A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

Exclusion Criteria

• •History or evidence of active or latent tuberculosis.
• •History or significant allergic reaction to any drug.
• •Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or within 5 half-lives of the respective medication, whichever is longer.
• •Current or expected need for oral intake of at least 10 mg prednisone per day or equivalent corticosteroid therapy.
• •History of acute inflammatory joint disease of different origin other than rheumatoid arthritis (rheumatoid arthritis patients).